The Effects of Selected Sesquiterpenes from Myrica rubra Essential Oil on the Efficacy of Doxorubicin in Sensitive and Resistant Cancer Cell Lines
Language English Country Switzerland Media electronic
Document type Journal Article
PubMed
28632185
PubMed Central
PMC6152637
DOI
10.3390/molecules22061021
PII: molecules22061021
Knihovny.cz E-resources
- Keywords
- ABCB1 transporter, Adriamycin, drug combinations, drug resistance, terpenes,
- MeSH
- Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy MeSH
- Doxorubicin pharmacology therapeutic use MeSH
- Drug Therapy, Combination MeSH
- Humans MeSH
- Drug Resistance, Multiple drug effects MeSH
- Monocyclic Sesquiterpenes MeSH
- Myrica chemistry MeSH
- Cell Line, Tumor MeSH
- Oils, Volatile chemistry MeSH
- Polycyclic Sesquiterpenes MeSH
- Cell Proliferation drug effects MeSH
- Sesquiterpenes pharmacology MeSH
- Drug Synergism MeSH
- Cell Survival drug effects MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- caryophyllene oxide MeSH Browser
- Doxorubicin MeSH
- humulene MeSH Browser
- Monocyclic Sesquiterpenes MeSH
- nerolidol MeSH Browser
- Oils, Volatile MeSH
- Polycyclic Sesquiterpenes MeSH
- Sesquiterpenes MeSH
- valencene MeSH Browser
β-caryophyllene oxide (CAO), α-humulene (HUM), trans-nerolidol (NER) and valencene (VAL) are constituents of the essential oil of Myrica rubra (MEO), which has significant antiproliferative effect in various cancer cell lines. In the present study, we compared the antiproliferative effect of these sesquiterpenes alone and in combination with the cytostatic drug doxorubicin (DOX) in cancer cell lines with different sensitivity to DOX. Two ovarian cancer cell lines (sensitive A2780 and partly resistant SKOV3) and two lymphoblast cancer cell lines (sensitive CCRF/CEM and completely resistant CEM/ADR) were used. The observed effects varied among sesquiterpenes and also differed in individual cell lines, with only VAL being effective in all the cell lines. A strong synergism of DOX with NER was found in the A2780 cells, while DOX acted synergistically with HUM and CAO in the SKOV3 cells. In the CCRF/CEM cells, a synergism of DOX with CAO and NER was observed. In resistant CEM/ADR cells, sesquiterpenes did not increase DOX efficacy, although they significantly increased accumulation of DOX (up to 10-times) and rhodamine-123 (substrate of efflux transporter ABCB1) within cancer cells. In conclusion, the tested sesquiterpenes were able to improve DOX efficacy in the sensitive and partly resistant cancer cells, but not in cells completely resistant to DOX.
See more in PubMed
Konig G.M., Wright A.D. New and unusual sesquiterpenes: Kelsoene, prespatane, epi-gamma-gurjunene, and t-cadinthiol, from the tropical marine sponge cymbastela hooperi. J. Org. Chem. 1997;62:3837–3840. doi: 10.1021/jo970015o. DOI
Ayer W.A., Browne L.M. Terpenoid metabolites of mushrooms and related basidiomycetes. Tetrahedron. 1981;37:2199–2248. doi: 10.1016/S0040-4020(01)97979-7. DOI
Finefield J.M., Sherman D.H., Kreitman M., Williams R.M. Enantiomeric natural products: Occurrence and biogenesis. Angew. Chem. 2012;51:4802–4836. doi: 10.1002/anie.201107204. PubMed DOI PMC
Bartikova H., Hanusova V., Skalova L., Ambroz M., Bousova I. Antioxidant, pro-oxidant and other biological activities of sesquiterpenes. Curr. Top. Med. Chem. 2014;14:2478–2494. doi: 10.2174/1568026614666141203120833. PubMed DOI
Yang B., Zhao Y.P., Lou C.H., Zhao H.J. Eupalinolide O, a novel sesquiterpene lactone from Eupatorium lindleyanum DC., induces cell cycle arrest and apoptosis in human MDA-MB-468 breast cancer cells. Oncol. Rep. 2016;36:2807–2813. doi: 10.3892/or.2016.5115. PubMed DOI
Wang J., Cui L., Feng L., Zhang Z.H., Song J., Liu D., Jia X.B. Isoalantolactone inhibits the migration and invasion of human breast cancer MDA-MB-231 cells via suppression of the p38 MAPK/NF-kB signaling pathway. Oncol. Rep. 2016;36:1269–1276. doi: 10.3892/or.2016.4954. PubMed DOI
Li H.Y., Li M.M., Wang G.C., Shao F.Y., Chen W.B., Xia C., Wang S., Li Y.L., Zhou G.X., Liu Z. EM23, a natural sesquiterpene lactone from elephantopus mollis, induces apoptosis in human myeloid leukemia cells through thioredoxin- and reactive oxygen species-mediated signaling pathways. Front Pharmacol. 2016;7:77. doi: 10.3389/fphar.2016.00077. PubMed DOI PMC
Van Haaften C., Boot A., Corver W.E., van Eendenburg J.D.H., Trimbos B.J.M.Z., van Wezel T. Synergistic effects of the sesquiterpene lactone, EPD, with cisplatin and paclitaxel in ovarian cancer cells. J. Exp. Clin. Cancer Res. 2015;34:38. doi: 10.1186/s13046-015-0157-2. PubMed DOI PMC
Quinn B.A., Dash R., Sarkar S., Azab B., Bhoopathi P., Das S.K., Emdad L., Wei J., Pellecchia M., Sarkar D., et al. Pancreatic cancer combination therapy using a BH3 mimetic and a synthetic tetracycline. Cancer Res. 2015;75:2305–2315. doi: 10.1158/0008-5472.CAN-14-3013. PubMed DOI PMC
Li X.Q., Lin Z.H., Zhang B., Guo L., Liu S., Li H., Zhang J.B., Ye Q.H. Beta-elemene sensitizes hepatocellular carcinoma cells to oxaliplatin by preventing oxaliplatin-induced degradation of copper transporter 1. Sci. Rep. 2016;6:21010. doi: 10.1038/srep21010. PubMed DOI PMC
Ambroz M., Bousova I., Skarka A., Hanusova V., Kralova V., Matouskova P., Szotakova B., Skalova L. The influence of sesquiterpenes from Myrica rubra on the antiproliferative and pro-oxidative effects of doxorubicin and its accumulation in cancer cells. Molecules. 2015;20:15343–15358. doi: 10.3390/molecules200815343. PubMed DOI PMC
Pillozzi S., Masselli M., de Lorenzo E., Accordi B., Cilia E., Crociani O., Amedei A., Veltroni M., D’Amico M., Basso G., et al. Chemotherapy resistance in acute lymphoblastic leukemia requires herg1 channels and is overcome by herg1 blockers. Blood. 2011;117:902–914. doi: 10.1182/blood-2010-01-262691. PubMed DOI
Mullighan C.G., Su X., Zhang J., Radtke I., Phillips L.A., Miller C.B., Ma J., Liu W., Cheng C., Schulman B.A., et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N. Engl. J. Med. 2009;360:470–480. doi: 10.1056/NEJMoa0808253. PubMed DOI PMC
Housman G., Byler S., Heerboth S., Lapinska K., Longacre M., Snyder N., Sarkar S. Drug resistance in cancer: An overview. Cancers. 2014;6:1769–1792. doi: 10.3390/cancers6031769. PubMed DOI PMC
Thorn C.F., Oshiro C., Marsh S., Hernandez-Boussard T., McLeod H., Klein T.E., Altman R.B. Doxorubicin pathways: Pharmacodynamics and adverse effects. Pharm. Genom. 2011;21:440–446. doi: 10.1097/FPC.0b013e32833ffb56. PubMed DOI PMC
Hill C.R., Jamieson D., Thomas H.D., Brown C.D., Boddy A.V., Veal G.J. Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo. Biochem. Pharmacol. 2013;85:29–37. doi: 10.1016/j.bcp.2012.10.004. PubMed DOI PMC
Langhansova L., Hanusova V., Rezek J., Stohanslova B., Ambroz M., Kralova V., Vanek T., Lou J.D., Yun Z.L., Yang J., et al. Essential oil from Myrica rubra leaves inhibits cancer cell proliferation and induces apoptosis in several human intestinal lines. Ind. Crop. Prod. 2014;59:20–26. doi: 10.1016/j.indcrop.2014.04.018. DOI
Ambroz M., Hanusova V., Skarka A., Bousova I., Kralova V., Langhasova L., Skalova L. Essential oil from Myrica rubra leaves potentiated antiproliferative and prooxidative effect of doxorubicin and its accumulation in intestinal cancer cells. Planta Med. 2016;82:89–96. doi: 10.1055/s-0035-1558083. PubMed DOI
Barla A., Topcu G., Oksuz S., Tumen G., Kingston D.G.I. Identification of cytotoxic sesquiterpenes from Laurus nobilis L. Food Chem. 2007;104:1478–1484. doi: 10.1016/j.foodchem.2007.02.019. DOI
Saab A.M., Guerrini A., Sacchetti G., Maietti S., Zeino M., Arend J., Gambari R., Bernardi F., Efferth T. Phytochemical analysis and cytotoxicity towards multidrug-resistant leukemia cells of essential oils derived from lebanese medicinal plants. Planta Med. 2012;78:1927–1931. doi: 10.1055/s-0032-1327896. PubMed DOI
Chou T.C. Drug combination studies and their synergy quantification using the chou-talalay method. Cancer Res. 2010;70:440–446. doi: 10.1158/0008-5472.CAN-09-1947. PubMed DOI
Morimoto H., Yonehara S., Bonavida B. Overcoming tumor necrosis factor and drug resistance of human tumor cell lines by combination treatment with anti-fas antibody and drugs or toxins. Cancer Res. 1993;53:2591–2596. PubMed
Kartner N., Riordan J.R., Ling V. Cell surface p-glycoprotein associated with multidrug resistance in mammalian cell lines. Science. 1983;221:1285–1288. doi: 10.1126/science.6137059. PubMed DOI
Morimoto H., Safrit J.T., Bonavida B. Synergistic effect of tumor necrosis factor-alpha- and diphtheria toxin-mediated cytotoxicity in sensitive and resistant human ovarian tumor cell lines. J. Immunol. 1991;147:2609–2616. PubMed
Silva R., Vilas-Boas V., Carmo H., Dinis-Oliveira R.J., Carvalho F., Bastos M.D., Remiao F. Modulation of p-glycoprotein efflux pump: Induction and activation as a therapeutic strategy. Pharmacol. Ther. 2015;149:1–123. doi: 10.1016/j.pharmthera.2014.11.013. PubMed DOI
Wu Q., Yang Z.P., Nie Y.Z., Shi Y.Q., Fan D.M. Multi-drug resistance in cancer chemotherapeutics: Mechanisms and lab approaches. Cancer Lett. 2014;347:159–166. doi: 10.1016/j.canlet.2014.03.013. PubMed DOI
Abdallah H.M., Al-Abd A.M., El-Dine R.S., El-Halawany A.M. P-glycoprotein inhibitors of natural origin as potential tumor chemo-sensitizers: A review. J. Adv. Res. 2015;6:45–62. doi: 10.1016/j.jare.2014.11.008. PubMed DOI PMC
Skarka A., Skarydova L., Stambergova H., Wsol V. Anthracyclines and their metabolism in human liver microsomes and the participation of the new microsomal carbonyl reductase. Chem. Biol. Interact. 2011;191:66–74. doi: 10.1016/j.cbi.2010.12.016. PubMed DOI